844476-72-8

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-(azidomethyl)-4-[(triphenylmethyl)thio]-, 1-methylethyl ester, (2S,4R)-
• CAS NO: 844476-72-8
• Molecular Formula: C28H30N4O2S
• Molecular Weight: 486.638
• Mol File: 844476-72-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-(azidomethyl)-4-[(triphenylmethyl)thio]-, 1-methylethyl ester, (2S,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-(azidomethyl)-4-[(triphenylmethyl)thio]-, 1-methylethyl ester, (2S,4R)-(844476-72-8)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-(azidomethyl)-4-[(triphenylmethyl)thio]-, 1-methylethyl ester, (2S,4R)-(844476-72-8)

Safety Data

• Hazardous Substances Data: 844476-72-8(Hazardous Substances Data)

Upstream product

• 169032-99-9 (2S,4S)-4-Chloro-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 393791-87-2 (2S,4R)-2-methanesulfonyloxymethyl-4-tritylsulfanylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 176306-17-5 (2S,4R)-4-tritylsulfanylpyrrolidine-1,2-dicarboxylic acid 1-tert-butyl-2-methyl diester 
• 337307-11-6 (2S,4R)-2-azidomethyl-4-tritylsulfanylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 337307-10-5 (2S,4R)-2-Hydroxymethyl-4-tritylsulfanyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 108-23-6 isopropyl chloroformate 
• 393792-04-6 (2S,4R)-2-azidomethyl-4-tritylsulfanylpyrrolidine 

Downstream Products

• 844476-74-0 (2S,4R)-2-[(2,5-difluorobenzylamino)methyl]-4-tritylsulfanylpyrrolidine-1-carboxylic acid isopropyl ester 
• 844476-73-9 (2S,4R)-2-aminomethyl-4-tritylsulfanylpyrrolidine-1-carboxylic acid isopropyl ester 

Relevant articles and documents

Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells

Endothelin-1 (ET-1) is mitogenic and/or antiapoptotic in human cancers, and antagonists to ET-1 receptors are under evaluation for cancer treatment. Inhibition of ET-1 activation by the endothelin-converting enzymes 1 a-d (ECE-1a-d; EC 3.4.24.71) represents another approach to block the ET-1 effect in cancer. To evaluate this potential, we synthesized and characterized a series of low nanomolar nonpeptidic thiol-containing ECE-1 inhibitors, and evaluated their effect, as well as the effect of inhibitors for the related metalloproteases neprilysin (NEP; EC 3.4.24.11) and angiotensin-converting enzyme (ACE; EC 3.4.15.1), on human glioblastoma cell growth. Only ECE-1 inhibitors inhibited DNA synthesis by human glioblastoma cells. Exogenous addition of ET-1 or bigET-1 to glioblastoma cells did not counterbalance the growth inhibition elicited by ECE-1 inhibitors, suggesting that ECE-1 inhibitors block the proliferation of human glioblastoma cells most likely via a mechanism not involving extracellular production of ET-1. This class of molecules may thus represent novel therapeutic agents for the potential treatment of human cancer.